Advanced search
Publication Cover
Patient Preference and Adherence Volume 13, 2019 - Issue
Submit an article Journal homepage
134
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Oncologists’ perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer

Yolanda ErasoSchool of Social Professions, London Metropolitan University, London, UKCorrespondence[email protected]
Pages 1311-1323 | Published online: 31 Jul 2019

References

  • Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–478. doi:10.1007/s10549-012-2114-522689091
  • Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013;138(1):325–328. doi:10.1007/s10549-013-2422-423400580
  • Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515–1524. doi:10.1038/bjc.2012.49423519057
  • Sabate E, ed. Adherence to Long-term Therapies: Evidence for Action. Geneva: The World Health Organisation; 2003 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed June 12, 2018
  • Ehrenzweig Sánchez Y. Modelos de cognición social y adherencia terapéutica en pacientes con cancer. Avances En Psicología Latinoamericana. 2007;25(1):7–21. Spanish.
  • Souza BF, Moraes JA, Inocenti A, Santos MA, Silva AEBC, Miasso AI. Mujeres con cáncer de mama en tratamiento con quimioterapéuticos: síntomas depresivos y adhesión al tratamiento. Rev Latino-Am Enfermagem. 2014;22(6):866–873. Spanish. doi:10.1590/0104-1169.3564.2491
  • Oliveira RS, Menezes JTL, Gonçalves MGL. Adesão à terapia hormonal adjuvante oral em pacientes com câncer de mama. Revista Brasileira De Cancerologia. 2012;58(4):593–601. Portuguese.
  • Peper FE, Esteban S, Terrasa SA. Evaluación de la adherencia primaria a medicamentos en pacientes con enfermedades crónicas afiliados al Seguro de Salud del Hospital Italiano de Buenos Aires: estudio de cohorte retrospectiva. Aten Primaria. 2018;50(2):96–105. Spanish. doi:10.1016/j.aprim.2017.01.01328521859
  • Brito C, Portela MC, Teixeira Leite de Vasconcellos M. Factors associated to persistence with hormonal therapy in women with breast cancer. Rev Saúde Pública. 2014;48(2):284–295. doi:10.1590/s0034-8910.201404800479924897050
  • GLOBOCAN: Cancer Today.. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages; 2018 Available from: http://gco.iarc.fr/today/home. Accessed 920, 2018.
  • Brett J, Fenlon D, Boulton M, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl). 2018;27(1):(201801)e12601. doi:10.1111/ecc12601.
  • Moon Z, Moss-Morris R, Hunter MS, Hughes LD. More than just side-effects: the role of clinical and psychosocial factors in non-adherence to tamoxifen. Br J Health Psychol. 2017;22(4):998–1018. doi:10.1111/bjhp.1227428940998
  • Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking – report for the National Coordinating Centre for NHS Service Delivery and Organisation Research and Development; 2005 Available from: http://www.netscc.ac.uk/netscc/hsdr/files/project/SDO_FR_08-1412-076_V01.pdf. Accessed 46, 2019 Accessed 13, 2019.
  • Horne R, Weinman J. Patient’s beliefs about prescribed medicines and their role in chronic physical illness. J Psychosom Res. 1998;47:555–567. doi:10.1016/S0022-3999(99)00057-4
  • Henry NL. Endocrine therapy toxicity: management options. Am Soc Clin Oncol Educ Book. 2014;e25–e30. doi:10.14694/EdBook_AM.2014.34.e2524857109
  • Harrow A, Dryden R, McCowan C, et al. A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open. 2014;4(6):e005285. doi:10.1136/bmjopen-2014-005285
  • Wuensch P, Hahne A, Haidinger R, et al. Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol. 2015;141(1):55–60. doi:10.1007/s00432-014-1779-z25085010
  • Lambert L, Balneaves LG, Fuchsia HA, Gotay CC. Patient reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2018;167(3):615–633. doi:10.1007/s10549-017-4520-129110151
  • Farias AJ, Ornelas IJ, Hohl SD, et al. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. Support Care Cancer. 2017;25(1):75–83. doi:10.1007/s00520-016-3389-627557832
  • Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431–439. doi:10.1097/01.mlr.0000257193.10760.7f17446829
  • Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat. 2013;137(3):829–836. doi:10.1007/s10549-012-2387-823263740
  • Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305–322. doi:10.2147/PPA.S13479228260867
  • Wheeler SB, Roberts MC, Bloom D, et al. Oncology providers’ perspectives on endocrine therapy prescribing and management. Patient Prefer Adherence. 2016;10:2007–2019. doi:10.2147/PPA.S9559427757021
  • Eraso Y. Factors influencing oncologists’ prescribing hormonal therapy in women with breast cancer: a qualitative study in Córdoba, Argentina. Int J Equity Healxth. 2019; 18 (1):35. doi:10.1186/s12939-019-0936-z
  • Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753–1760. doi:10.1177/104973231561744426613970
  • Greer JA, Amoyal N, Nisotel LA, et al. Systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–376. doi:10.1634/theoncologist.2015-040526921292
  • Roberts J. Local Action on Health Inequalities. Improving Health Literacy to Reduce Health Inequalities. London:Public Health England; 2015 Available from: http://www.instituteofhealthequity.org/resources-reports/local-action-on-health-inequalities-health-literacy-to-reduce-health-inequalities/health-literacy-improving-health-literacy-to-reduce-health-inequalities-full.pdf. Accessed August 10, 2018.
  • Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation due to treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30:936–942. doi:10.1200/JCO.2011.38.026122331951
  • Consenso Nacional Inter-Sociedades sobre Cáncer de Mama: Pautas para el seguimiento de pacientes asintomáticas luego del tratamiento primario con intención curativa; 2007 Available from: https://www.ama-med.org.ar/images/uploads/files/consenso%20pacientes%20asintom%C3%A1ticos%202007.pdf. Accessed 923, 2018.
  • Wickersham K, Happ MB, Bender CM. “Keeping the boogie man away”: medication self-management among women receiving anastrozole therapy. Nurs Res Pract. 2012;2012:462121 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543807/. Accessed Feb 4, 2019.23326655
  • Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97–102. doi:10.1016/j.pec.2004.10.00516198223
  • Brett J, Boulton M, Fenlon D, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence. 2018;12:291–300. doi:10.2147/PPA.S17606729497284
  • Wengström Y, Aapro M, Leto Di Priolo S, Cannon H, Georgiou V. Patients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast. 2007;16(5):462–468. doi:10.1016/j.breast.2007.02.00717449249
  • Farias AJ, Hansen RN, Zeliadt SB, Ornelas IJ, Li CI. Thompson B factors associated with adherence to adjuvant endocrine therapy among privately insured and newly diagnosed breast cancer patients: a quantile regression analysis. J Manag Care Spec Pharm. 2016;22(8):969–978.27459660
  • Pan Y, Heisig SR, von Blanckenburg P, et al. Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study. Breast Cancer Res Treat. 2018;168(3):667–677. doi:10.1007/s10549-017-4637-229330625
  • Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.
  • Zomahoun HTV, Guénette L, Grégoire JP, et al. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. Int J Epidemiol. 2017;46(2):589–602. doi:10.1093/ije/dyw31727864410
  • Ramirez AG, Wildes KA, Nápoles-Springer A, Pérez-Stable E, Talavera G, Rios E. Physician gender differences in general and cancer-specific prevention attitudes and practices. J Cancer Educ. 2009;24(2):85–93. doi:10.1080/0885819080266439619431022
  • Jefferson L, Bloor K, Birks Y, Hewitt C, Bland M. Effect of physicians’ gender on communication and consultation length: a systematic review and meta-analysis. J Health Serv Res Policy. 2013;18(4):242–248. doi:10.1177/135581961348646523897990
  • Dirección General de Estadísticas y Censos Provincia de la Córdoba. [https://estadistica.cba.gov.ar/] Provincia de Córdoba según departamentos. Población según cobertura de salud en mujeres por grandes grupos de edad; 2010 Available from: https://datosestadistica.cba.gov.ar/dataset/cobertura-de-salud. Accessed 8 27, 2018.
  • APROSS Cartilla de Prestadores – Oncología. Available from: http://www.apross.gov.ar/cartilla-de-prestadores.aspx. 2016 Accessed 520, 2016.
  • Ritchie J, Spencer L. Qualitative data analysis for applied policy research In: Huberman M, Miles M, editors. The Qualitative Researcher’s Companion. London: Sage; 2002:305–329.
  • Camacho FT, Tan X, Alcalá HE, Shah S, Anderson RT, Balkrishnan R. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in Medicare breast cancer survivors. Medicine (Baltimore). 2017;96(24):e7147. doi:10.1097/MD.000000000000714728614244
  • Tan X, Camacho F, Marshall VD, Donohoe J, Anderson RT, Balkrishnan R. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer. Res Social Adm Pharm. 2017;13(4):796–810. doi:10.1016/j.sapharm.2016.08.00427641308
  • Engelhardt EG, Pieterse AH, van der Hout A, et al. Use of implicit persuasion in decision making about adjuvant cancer treatment: a potential barrier to shared decision making. Eur J Cancer. 2016;66:55–66. doi:10.1016/j.ejca.2016.07.01127525573
  • The Economist Intelligence Unit. Cancer control, access and inequality in Latin America: a tale of light and shadow; 2017 Available from: https://perspectives.eiu.com/sites/default/files/Cancercontrol,accessandinequalityinLatinAmerica.pdf. Accessed 810, 2018.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-015894097
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352. doi:10.1016/S0140-6736(15)61074-126211827
  • Karanikolos M, Ellis L, Coleman MP, McKee M. Health systems performance and cancer outcomes. J Natl Cancer Inst Monogr. 2013;46:7–12. doi:10.1093/jncimonographs/lgt00323962507

Reference

  • Eraso Y. Factors influencing oncologists’ prescribing hormonal therapy in women with breast cancer: a qualitative study in Córdoba, Argentina. Int J Equity Health. 2019; 18(1):35. doi:10.1186/s12939-019-0936-z

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.